L

LTR Pharma Ltd
ASX:LTP

Watchlist Manager
LTR Pharma Ltd
ASX:LTP
Watchlist
Price: 0.725 AUD -4.61% Market Closed
Market Cap: 111.5m AUD
Have any thoughts about
LTR Pharma Ltd?
Write Note

LTR Pharma Ltd
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

LTR Pharma Ltd
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
L
LTR Pharma Ltd
ASX:LTP
Interest Income Expense
-AU$14.7k
CAGR 3-Years
-6%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mayne Pharma Group Ltd
ASX:MYX
Interest Income Expense
AU$679k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Neuren Pharmaceuticals Ltd
ASX:NEU
Interest Income Expense
AU$1.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Botanix Pharmaceuticals Ltd
ASX:BOT
Interest Income Expense
AU$46.6k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Probiotec Ltd
ASX:PBP
Interest Income Expense
-AU$6m
CAGR 3-Years
-40%
CAGR 5-Years
-37%
CAGR 10-Years
-15%
Arovella Therapeutics Ltd
ASX:ALA
Interest Income Expense
-AU$8.6k
CAGR 3-Years
36%
CAGR 5-Years
41%
CAGR 10-Years
N/A
No Stocks Found

LTR Pharma Ltd
Glance View

Market Cap
101.1m AUD
Industry
Pharmaceuticals

LTR Pharma Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Brisbane, Queensland. The company went IPO on 2023-12-11. LTR Pharma Limited is an Australia-based clinical-stage biopharmaceutical company. The firm is focused on holistically improving men’s health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction (ED). Its lead product SPONTAN is set apart from existing ED therapies by its mechanism of action-intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work in 10 minutes or less. SPONTAN (SDS-089) is a novel intranasal drug (PDE5) delivery platform for Erectile Dysfunction.

LTP Intrinsic Value
0.008 AUD
Overvaluation 99%
Intrinsic Value
Price
L

See Also

What is LTR Pharma Ltd's Interest Income Expense?
Interest Income Expense
-14.7k AUD

Based on the financial report for Jun 30, 2024, LTR Pharma Ltd's Interest Income Expense amounts to -14.7k AUD.

What is LTR Pharma Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
-6%

Over the last year, the Interest Income Expense growth was 24%. The average annual Interest Income Expense growth rates for LTR Pharma Ltd have been -6% over the past three years .

Back to Top